咨询客服 咨询客服

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting

Abstract:
Objectives To assess incidence rates (IRs) of VTE in patients with rheumatoid arthritis (RA) on different DMARDs and DMARD switchers. Methods Adults with RA on a DMARD between 2007 and 2017 were studied in a US claims database. Conventional synthetic DMARD (csDMARD) users, first biologic/targeted synthetic DMARD (b/tsDMARD) users and b/tsDMARD switchers (from a b/tsDMARD to another b/tsDMARD) were followed for inpatient VTE (pulmonary embolism (PE)/deep vein thrombosis (DVT)). Crude and adjusted IR and 95% CIs of VTE were estimated. HRs for VTE were estimated via Cox regression. VTE risk was also evaluated by number of switches between b/tsDMARDs and in patients without a VTE history. Results The age and sex standardised IR (95%\u2009CI) of VTE (per 100 person-years) was 0.86 (0.70 to 1.03), 0.60 (0.52 to 0.68) and 0.58 (0.51 to 0.65) for b/tsDMARD switchers, first b/tsDMARD users and csDMARD users, respectively. After adjustment, b/tsDMARD switchers had an increased risk of VTE, compared with csDMARD users, HRadj (95%\u2009CI) being 1.36 (1.16 to 1.58), 1.36 (1.13 to 1.63) and 1.47 (1.18 to 1.83) for VTE, DVT and PE, respectively. Compared with first b/tsDMARD users, the HRadj (95%\u2009CI) for VTE was 1.35 (1.15 to 1.60) for first b/tsDMARD switchers and 1.48 (1.19 to 1.85) for second b/tsDMARD switchers. Conclusions In RA, b/tsDMARD switchers have a higher VTE risk compared with csDMARD users and first b/tsDMARD users. Switching b/tsDMARDs may be a proxy for higher disease severity or poorly controlled RA and an important confounder to consider in obtaining unbiased estimates of VTE risk in observational RA safety studies.
Author Listing: Huifang Liang;Raghava Danwada;Dianlin Guo;Jeffrey R. Curtis;Ryan D Kilpatrick;Barbara A. Hendrickson;Syed S. Islam
Volume: 5
Pages: None
DOI: 10.1136/rmdopen-2019-001013
Language: English
Journal: RMD Open

RMD Open

RMD OPEN

影响因子:4.7
是否综述期刊:否
是否OA:是
是否预警:不在预警名单内
发行时间:-
ISSN:2056-5933
发刊频率:-
收录数据库:SCIE/Scopus收录/DOAJ开放期刊
出版国家/地区:ENGLAND
出版社:BMJ PUBLISHING GROUP

期刊介绍

年发文量 268
国人发稿量 24
国人发文占比 8.81%
自引率 4.3%
平均录取率 -
平均审稿周期 14 Weeks
版面费 1,950 GBP
偏重研究方向 RHEUMATOLOGY-
期刊官网 https://rmdopen.bmj.com
投稿链接 -

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
97.76% 99.46% 0.00% 2.06%

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

时间 预警情况
2025年03月发布的2025版 不在预警名单中
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级:Q1区

版本 按学科 分区
WOS期刊SCI分区
(2021-2022年最新版)
RHEUMATOLOGY Q1

中科院分区

版本 大类学科 小类学科 Top期刊 综述期刊
医学
2区
RHEUMATOLOGY
风湿病学
2区
2021年12月
基础版
医学
2区
RHEUMATOLOGY
风湿病学
3区
2021年12月
升级版
医学
2区
RHEUMATOLOGY
风湿病学
2区
2022年12月
最新升级版
医学
2区
RHEUMATOLOGY
风湿病学
2区